Across TCGA pan-cancer cohorts, MIR29B2CHG Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MIR29B2CHG data layer compared with 30 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher MIR29B2CHG Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR29B2CHG expression acts as an unfavorable survival marker.

ACC and KIRC are the cancer types where MIR29B2CHG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.102	0.674	<.001	45	view →
KIRC	OS	Median	All	0.152	0.874	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: MIR29B2CHG tumor-vs-normal RNA expression · all MIR29B2CHG data types